Ph.D. Economist and Investor Nomi Prins is releasing details on her next stunning prediction… It involves “liquid energy” that is promising to trigger an energy revolution 117x bigger than all of the hottest tech trends combined. Sign up for a Robinhood brokerage account to buy or sell Biogen stock and options commission-free. Despite lingering macro issues, the biotech industry is expected to witness robust growth. Moreover, amid rising medical needs and chronic diseases, research and development in the biotech sector are expected… Live educational sessions using site features to explore today’s markets.

Biogen Inc stock

We are continuously working to improve our web experience, and encourage users to Contact Us for feedback and Forex accommodation requests. Join thousands of traders who make more informed decisions with our premium features. needs to review the security of your connection before proceeding. The compound annual growth rate measures an investment’s annual growth rate over a period of time, assuming profits are reinvested at the end of each year. IBD Videos Get market updates, educational videos, webinars, and stock analysis.

Biogen in Pole Position After Roche’s Alzheimer’s Drug Disappoints

Aduhelm was approved as the firm’s first Alzheimer’s disease therapy in June 2021. 28 Wall Street research analysts have issued “buy,” “hold,” and “sell” ratings for Biogen in the last year. There are currently 8 hold ratings and 20 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should “buy” BIIB shares.

  • A triple bottom is a bullish chart pattern used in technical analysis that is characterized by three equal lows followed by a breakout above resistance.
  • By using this site, you are agreeing to security monitoring and auditing.
  • To calculate, start with total shares outstanding and subtract the number of restricted shares.
  • For more information, please see the SEC’s Web Site Privacy and Security Policy.
  • Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.
  • The information on this site is in no way guaranteed for completeness, accuracy or in any other way.

The company provided EPS guidance of $16.50-$17.15 for the period, compared to the consensus earnings per share estimate of $16.49. The company issued revenue guidance of $10.00 billion-$10.15 billion, compared to the consensus revenue estimate of $10.00 billion. Money Flow Uptick/Downtick RatioMoney flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an “uptick” in price and the value of trades made on a “downtick” in price.

Health Care Stocks Whale Activity In Today’s Session

Unique to, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. Results dotbig are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating.

A triple bottom is a bullish chart pattern used in technical analysis that is characterized by three equal lows followed by a breakout above resistance. A pullback refers to the falling back of a price of a stock or commodity from its recent pricing peak. The offers that appear in this table are from partnerships from which Investopedia receives compensation.

Stocks Turned $10,000 To $190,479 In 10 Months

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company’s price per share by its earnings per share. Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis ; SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer’s disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis,…

Key Executives

“Much of Biogen’s future direction had rested on the outcome of this Phase 3 study of lecanemab in Alzheimer’s disease,” RBC’s Abrahams said. Now that the lecanemab data are clear, SVB’s Goodman expects Biogen to announce a new CEO “in the next few months.” “We believe it’s still too early to say for sure that lecanemab will be a multibillion-dollar opportunity, but this likelihood is certainly higher now,” she said in a note. Also key for Biogen dotbig stock, just 21.3% of patients who received lecanemab experienced brain swelling known as amyloid-related imaging abnormalities, or ARIA. ARIA is a common side effect of amyloid-targeting drugs like lecanemab and Aduhelm. For lecanemab, the results were “rather clean,” Mizuho Securities analyst Salim Syed said in a note. At 18 months, patients who received lecanemab showed a 27% slower decline in cognition compared with placebo recipients.

Biogen beats revenue expectations in the third quarter

You can read more about the power of momentum in assessing share price movements on Stockopedia. Biogen’s BIIB, +4.96% stock is rising again as investors double down on the company’s promising yet still experimental treatment for Alzheimer’s disease. Even though many stocks have fallen sharply in price, not BIIB stock all are bargains — investors must remains selective. To see a complete breakdown of any of the ETFs included in the table below, including sector, market cap, and country allocations, click on the ticker symbol. Biogen reported an EPS of $4.77 in its last earnings report, beating expectations of $4.126.

Billionaire investor and hedge fund manager Steve Cohen’s Point 72 Asset Management has disclosed some interesting stakes in… 394 employees have rated Forex Biogen Chief Executive Officer Michel Vounatsos on Michel Vounatsos has an approval rating of 86% among the company’s employees.

Liquidity Ratio

High institutional ownership can be a signal of strong market trust in this company. In the past three months, Biogen insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,552,832.00 in company stock. MarketRank stock price of Biogen Inc is calculated as an average of available category scores, with extra weight given to analysis and valuation. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.

Comments are closed.

Google+ Google+